1. Catechol-O-methyltransferase genotype (Val158met) modulates cancer-related fatigue and pain sensitivity in breast cancer survivors

   • César Fernández-de-las-Peñas
   • Carolina Fernández-Lao
   • Manuel Arroyo-Morales

   Preclinical Study 04 September 2011 Pages: 405 - 412

2. Thinking beyond the tumor to better understand chronic symptoms in breast cancer survivors

   • N. Lynn Henry
   • Daniel J. Clauw

   Invited Commentary 11 October 2011 Pages: 413 - 416

3. Effect of anti-DR5 and chemotherapy on basal-like breast cancer

   • Patsy G. Oliver
   • Albert F. LoBuglio
   • Donald J. Buchsbaum

   Preclinical study 07 September 2011 Pages: 417 - 426

   

4. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer

   • Emi Tokuda
   • Yuko Seino
   • Yuri Yamaguchi

   Preclinical Study 11 September 2011 Pages: 427 - 436

   

5. Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity

   • Angelina I. Londoño-Joshi
   • Patsy G. Oliver
   • Donald J. Buchsbaum

   Preclinical Study 14 September 2011 Pages: 437 - 445

   

6. C6-Ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth

   • Margaret Flowers
   • Gemma Fabriás
   • Myles C. Cabot

   Preclinical Study 21 September 2011 Pages: 447 - 458

   

7. The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin

   • Osvaldo Pontiggia
   • Rocio Sampayo
   • Marina Simian

   Preclinical study 21 September 2011 Pages: 459 - 471

   

8. The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells

   • Yi Ma
   • Xiaomeng Hao
   • Jin Zhang

   Preclinical study 23 September 2011 Pages: 473 - 485

   

9. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells

   • Chunyu Wang
   • Julie Ann Mayer
   • Powel H. Brown

   Preclinical Study 24 September 2011 Pages: 487 - 500

   

10. Vascular proliferation is a prognostic factor in breast cancer

    • Jarle B. Arnes
    • Ingunn M. Stefansson
    • Lars A. Akslen

    Preclinical Study 27 September 2011 Pages: 501 - 510

    

11. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors

    • Carmine Fedele
    • Gennaro Riccio
    • Claudia De Lorenzo

    Preclinical study 27 September 2011 Pages: 511 - 521

    

12. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice

    • Penelope D. Ottewell
    • Hannah K. Brown
    • Ingunn Holen

    Preclinical Study 29 September 2011 Pages: 523 - 536

    

13. Quality of life among Egyptian women with breast cancer after sparing mastectomy and immediate autologous breast reconstruction: a comparative study

    • Adel Denewer
    • Omar Farouk
    • Mosab Shetiwy

    Preclinical Study 29 September 2011 Pages: 537 - 544

14. A comparison of quality of life of early breast cancer patients treated with accelerated partial breast irradiation versus whole breast irradiation in China

    • Zhen-Yu He
    • Qin Tong
    • Xun-Xing Guan

    Preclinical study 29 September 2011 Pages: 545 - 552

    

15. Improving communication of breast cancer recurrence risk

    • Noel T. Brewer
    • Alice R. Richman
    • Lisa A. Carey

    Preclinical Study 01 October 2011 Pages: 553 - 561

    

16. IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways

    • Tania Benatar
    • Wenyi Yang
    • Arun Seth

    Preclinical study 14 October 2011 Pages: 563 - 573

    

17. EpCAM expression is an indicator of recurrence in basal-like breast cancer

    • Ayodeji J. Agboola
    • E. Claire Paish
    • Andrew R. Green

    Preclinical Study 15 October 2011 Pages: 575 - 582

    

18. Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours

    • Karolina Holm
    • Johan Staaf
    • Åke Borg

    Preclinical study 16 October 2011 Pages: 583 - 594

    

19. Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts

    • P. Cottu
    • E. Marangoni
    • D. Decaudin

    Preclinical study 16 October 2011 Pages: 595 - 606

    

20. GRB7 is required for triple-negative breast cancer cell invasion and survival

    • Orsi Giricz
    • Verónica Calvo
    • Paraic A. Kenny

    Preclinical Study 18 October 2011 Pages: 607 - 615

    

21. Life stage differences in mammary gland gene expression profile in non-human primates

    • Petra Stute
    • Sonja Sielker
    • J. Mark Cline

    Preclinical study 25 October 2011 Pages: 617 - 634

    

22. Lipidomic approach to identify patterns in phospholipid profiles and define class differences in mammary epithelial and breast cancer cells

    • M. Luísa Dória
    • Zita Cotrim
    • M. Rosário Domingues

    Preclinical study 25 October 2011 Pages: 635 - 648

    

23. Epigenetic silencing of the tumor suppressor klotho in human breast cancer

    • Tami Rubinek
    • Michal Shulman
    • Ido Wolf

    Preclinical Study 22 October 2011 Pages: 649 - 657

    

24. Rates of upgrade to malignancy for 271 cases of flat epithelial atypia (FEA) diagnosed by breast core biopsy

    • Alexandre Peres
    • Emmanuel Barranger
    • Pascal Cherel

    Preclinical study 01 November 2011 Pages: 659 - 666

    

25. Upper limb progressive resistance training and stretching exercises following surgery for early breast cancer: a randomized controlled trial

    • Sharon L. Kilbreath
    • Kathryn M. Refshauge
    • Ross Hansen

    Clinical Trial 29 January 2012 Pages: 667 - 676

    

26. Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score

    • Alan H. B. Wu
    • Wendy Lorizio
    • Elad Ziv

    Clinical Trial 01 February 2012 Pages: 677 - 683

    

27. Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results

    • Shunji Takahashi
    • Takuji Iwase
    • Shinzaburo Noguchi

    Clinical Trial 04 February 2012 Pages: 685 - 693

    

28. Which prediction models best identify additional axillary disease after a positive sentinel node biopsy for breast cancer?

    • Tanya S. Berrang
    • Mary Lesperance
    • Ivo A. Olivotto

    Clinical Trial 25 February 2012 Pages: 695 - 702

    

29. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence

    • Yi Ling Teo
    • Manit Saetaew
    • Alexandre Chan

    Clinical Trial 28 February 2012 Pages: 703 - 711

    

30. Invasive lobular breast cancer: subtypes and outcome

    • Monica Iorfida
    • Eugenio Maiorano
    • Giuseppe Viale

    Clinical Trial 08 March 2012 Pages: 713 - 723

    

31. Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the BRCA2 gene

    • Michelle G. Rath
    • Farnoosh Fathali-Zadeh
    • Barbara Burwinkel

    Epidemiology 08 January 2012 Pages: 725 - 734

    

32. Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening

    • Kelly A. Metcalfe
    • Nida Mian
    • Steven A. Narod

    Epidemiology 13 January 2012 Pages: 735 - 740

    

33. Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes

    • Byeong-Woo Park
    • Seho Park
    • Kyong Sik Lee

    Epidemiology 29 January 2012 Pages: 741 - 751

    

34. Health-related quality of life in male breast cancer patients

    • Christoph Kowalski
    • Petra Steffen
    • Holger Pfaff

    Epidemiology 08 February 2012 Pages: 753 - 757

    

35. Economic evaluation of the 70-gene prognosis-signature (MammaPrint^®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan

    • Masahide Kondo
    • Shu-Ling Hoshi
    • Masakazu Toi

    Epidemiology 08 February 2012 Pages: 759 - 768

    

36. The single-nucleotide polymorphisms +936 C/T VEGF and −710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population

    • Patricia Rodrigues
    • Jessica Furriol
    • Pilar Eroles

    Epidemiology 08 February 2012 Pages: 769 - 778

    

37. Increased diagnosis and detection rates of carcinoma in situ of the breast

    • J. A. Glover
    • F. J. Bannon
    • L. J. Murray

    Epidemiology 14 February 2012 Pages: 779 - 784

    

38. Alcohol, genetics and risk of breast cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

    • Catherine A. McCarty
    • Douglas J. Reding
    • Regina G. Ziegler

    Epidemiology 14 February 2012 Pages: 785 - 792

    

39. Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen

    • N. G. L. Jager
    • H. Rosing
    • J. H. Beijnen

    Brief Report Open access 03 March 2012 Pages: 793 - 798

    

40. Mesothelin, a novel immunotherapy target for triple negative breast cancer

    • Julia Tchou
    • Liang-Chuan Wang
    • Paul J. Zhang

    Brief Report 15 March 2012 Pages: 799 - 804

    

41. The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians

    • Irene Catucci
    • Paolo Verderio
    • Paolo Peterlongo

    Letter to the Editor 14 March 2012 Pages: 805 - 807

42. Germline mutations 657del5 and 643C>T (R215W) in NBN are not likely to be associated with increased risk of breast cancer in Czech women

    • Martin Mateju
    • Petra Kleiblova
    • Petr Pohlreich

    Letter to the Editor 11 April 2012 Pages: 809 - 811